Chemotherapy for advanced epithelial ovarian cancer.
In the past decade there have been significant improvements in chemotherapy for advanced ovarian cancer. Platinum-based chemotherapy has improved response rates and, to a lesser degree, prolonged survival. Taxol and its combination with platinum drugs holds the promise for even further improvements in survival. Clinical trials are evaluating issues such as dose-intensity, new combinations, and drug resistance.